Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicenna Therapeutics Corp (MDNA.TO)

Medicenna Therapeutics Corp (MDNA.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 68,397
  • Shares Outstanding, K 83,411
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,805 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.68
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings $-0.06 on 11/12/25
  • Next Earnings Date 02/12/25
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.79 +1.27%
on 02/09/26
1.04 -23.08%
on 01/22/26
-0.14 (-14.89%)
since 01/09/26
3-Month
0.79 +1.27%
on 02/09/26
1.78 -55.06%
on 12/10/25
-0.65 (-44.83%)
since 11/07/25
52-Week
0.78 +2.56%
on 06/27/25
1.97 -59.39%
on 10/27/25
-0.47 (-37.01%)
since 02/07/25

Most Recent Stories

More News
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10 th December, 2025 Fondazion Melanoma...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)
Stocks in play: Medicenna Therapeutics Corp.

Today announced NEO-CYT, a randomized, investigator initiated neoadjuvant trial testing MDNA11, a long ...

MDNA.TO : 0.80 (-2.44%)
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)
Medicenna Therapeutics Announces Participation in Upcoming Conferences

TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)
Stocks in play: Medicenna Therapeutics Corp.

Announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in the ROTH ...

MDNA.TO : 0.80 (-2.44%)
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

TORONTO and HOUSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...

MDNAF : 0.5805 (-3.25%)
MDNA.TO : 0.80 (-2.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates...

See More

Key Turning Points

3rd Resistance Point 0.90
2nd Resistance Point 0.87
1st Resistance Point 0.85
Last Price 0.80
1st Support Level 0.80
2nd Support Level 0.77
3rd Support Level 0.75

See More

52-Week High 1.97
Fibonacci 61.8% 1.52
Fibonacci 50% 1.38
Fibonacci 38.2% 1.23
Last Price 0.80
52-Week Low 0.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar